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Abstract Positron emission tomography (PET) alone or
in combination with MRI is increasingly assuming a cen-
tral role in the development of diagnostic and therapeutic
strategies for brain tumours with the aim of addressing
tumour heterogeneity, assisting in patient stratification, and
contributing to predicting treatment response. The 18 kDa
translocator protein (TSPO) is expressed in high-grade
gliomas, while its expression is comparatively low in
normal brain. In addition, the evidence of elevated TSPO in
neoplastic cells has led to studies investigating TSPO as a
transporter of anticancer drugs for brain delivery and a
selective target for tumour tissue. The TSPO therefore
represents an ideal candidate for molecular imaging stud-
ies. Knowledge of the biology of TSPO in normal brain
cells, in-depth understanding of TSPO functions and
biodistribution in neoplastic cells, accurate methods for
quantification of uptake of TSPO tracers and pharmacoki-
netic data regarding TSPO-targeted drugs are required
before introducing TSPO PET and TSPO-targeted treat-
ment in clinical practice. In this review, we will discuss the
impact of preclinical PET studies and the application of
TSPO imaging in human brain tumours, the advantages and
disadvantages of TSPO imaging compared to other
imaging modalities and other PET tracers, and pathology
studies on the extent and distribution of TSPO in gliomas.
The suitability of TSPO as molecular target for treatment
of brain tumours will also be the appraised.
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Introduction
PET imaging has increasingly been explored in the field of
neuro-oncology for pre-operative prediction of tumour
grade, monitoring of disease progression and response to
treatment, and to acquire information about the expression
and distribution of molecules that can be targeted for
treatment [1].
The mitochondrial translocator protein (TSPO) is one of
the PET imaging target molecules that has been investi-
gated in the last two decades [2, 3]. The TSPO offers
several advantages in the study of brain tumours, because
its expression is increased in tumour cells but low in the
normal brain and the expression can be visualized and
quantified with PET imaging [4]. The first studies looking
at the density and distribution of TSPO with autoradiog-
raphy in mouse and postmortem human brain sections date
over two decades [5–8]. The first preclinical and clinical
PET imaging studies suggested an application of TSPO
imaging in clinical practice [9, 10], but during the 20 years
that followed, research almost exclusively focused on
gliomas despite the great variety, heterogeneity and com-
plexity of tumours of the central nervous system (CNS).
This review aims to appraise the literature and discuss
the advantages and challenges of investigating the TSPO as
a target of molecular imaging for CNS tumours.
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The complexity and heterogeneity of CNS tumours
An accurate classification of CNS tumours is essential for
the planning, development and interpretation of molecular
imaging studies, validation of tracers, correlations with
outcome, response to treatment and translation of preclin-
ical studies into clinical application.
Tumours of the CNS comprise more than 120 types.
They are classified and graded according to the World
Health Organization (WHO) (WHO Blue Book) [11]. The
WHO blue book represents a set of consensus guidelines
aiming at establishing criteria for clinical practice. The
Blue Book distinguishes clinico-pathological entities,
variants and histological patterns. An entity has distinctive
morphology, location, age distribution and biologic beha-
viour. Variants can be identified histologically and have
some relevance for clinical outcome, but are mostly parts
of a defined entity. Patterns of differentiation are visually
identifiable by nature without distinct clinical or patho-
logical features [11].
The WHO Blue Book also recommends a histological
grade. Grading is a ‘malignancy scale’ intended to predict
the natural biological behaviour of a neoplasm. In general,
grade I applies to lesions with low proliferative potential
and often cured with surgery. Grade II defines tumours that
are usually infiltrative and often recur despite their low
growth potential. Some grade II tumours progress to higher
grade. Grade III defines lesions with histological evidence
of malignancy and WHO grade IV is assigned to tumour
associated with rapid progression and a fatal outcome. The
WHO grade is not an absolute predictor of outcome. Other
factors such as age, performance status, location, extent of
surgical resection and genetic alterations are relevant to an
overall estimate of prognosis [11].
An in-depth understanding of the molecular and genetic
basis of CNS tumours has led to a significant improvement
of diagnostic accuracy and ability to estimate the outcome
and to guide the treatment of several tumour entities [12].
In addition to the histotype and grade, molecular and
genetic features should be considered in molecular imaging
studies that are designed to stratify patients or identify
measures of outcome.
Preclinical models: in vivo imaging models
and in vitro studies
PET imaging in small animals became available at the end
of the 1990s [13, 14], about 10 years after the initial studies
on TSPO. The recent introduction of small animal devices
with high resolution and the possibility of co-registering
PET and MRI have boosted preclinical research on CNS
tumours [14]. So far, preclinical imaging studies on TSPO
in CNS tumours have focused mostly on assessing the
suitability of second-generation TSPO ligands in glioma
models.
Buck et al. first tested [18F] PBR06 in rat implanted
with the C6 glioma cell line [15]. The signal was fourfold
higher than in the normal brain and its accumulation in
neoplastic tissue closely reflected TSPO protein levels
measured in the tissue. The authors attempted to fit a
compartmental model (the classic two-tissue compartment
model with four rate constants) to the dynamic PET data,
but did not obtain meaningful estimates of the volume of
distribution (Vt) and had to adopt simplified graphical
approaches to obtain stable Vt estimates. This aspect of
their work is relevant, because it highlights the complexity
of the quantification for TSPO tracers. The heterogeneity
of cellular distribution of TSPO that is already present in
the normal brain (vascular, parenchyma) is compounded in
and around tumours by the variability of vascularization,
perfusion and cellularity, typical of high-grade gliomas.
Interestingly, Buck and colleagues reported slightly higher
uptake in the peripheral regions of the tumour and sug-
gested that PET imaging can identify the proliferative and
infiltrative components of gliomas. This result contrasts
with studies based on serial stereotactic biopsies that
demonstrated decreased proliferation in the infiltrative
edge of gliomas compared to the tumour centre, while
adhesion molecules were more abundant at the periphery
to confer a migratory, infiltrative phenotype [16]. The
same group at the Vanderbilt University subsequently
evaluated [18F]DPA-714 in a similar rat model [17]. Like
[18F]PBR06, [18F]DPA-714 uptake correlated with TSPO
protein levels in the tissue, but a head-to-head comparison
of the two tracers showed better retention of [18F]DPA-
714. More recently, they generated the novel ligand [18-
F]VUIIS1008 showing 36-fold higher affinity than its
parent compound [18F]DPA-714 [18]. [18F]VUIIS1008
had greater tumour avidity, lower uptake in the normal
brain, better tumour-to-background ratio and higher
binding potential than [18F]DPA-714. However, the per-
fusion rate of [18F]DPA-714 (K1) was much higher than
[18F]VUIIS1008, suggesting that more tracer crossed the
blood brain barrier (BBB) while the affinity for TSPO was
higher for [18F]VUIIS1008. This evidence indicates that
[18F]DPA-714 performed slightly better if the simple
SUVs (integrated radioactivity) was used as a measure of
uptake. A kinetic modelling should have been applied to
see an improved ratio for [18F]VUIIS1008. [18-
F]VUIIS1008 and its parent compounds have limitations
such as the still too high accumulation in the normal brain
that could obscure gliomas with low TSPO expression. In
addition, in vivo metabolism requires a corrected plasma
input function for modelling, long dynamic PET acquisi-
tions and compartmental analysis that are not always
possible in a routine clinical practice.
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[18F]DPA-714 was also evaluated by Winkeler and
colleagues in an intracranial rat glioma model where the 9L
glioma cell line was implanted into three different rat
strains, including Fischer, Wistar and Sprague–Dawley
[19]. In keeping with the previous study, the results showed
satisfactory uptake at the site of glioma as compared to the
contralateral brain hemisphere and cerebellum. Immunos-
tains on tissue demonstrated that TSPO was mostly
restricted to tumour cells with a contribution of glioma-
associated microglial/macrophages (GAMs), but not reac-
tive astrocytes around the lesion. 18F-DPA-714 was also
tested in the same model to monitor the efficacy of eru-
fosine on gliomas [20].
Finally, the recent preclinical study by Buck and col-
leagues is of potential relevance to the progress of
molecular imaging in human gliomas [21]. They used
human low- and high-grade glioma samples established
orthotopically in NOD/SCID mice and then passaged into
athymic rats. Unlike conventional models, this xenotrans-
plants allowed evaluation of invasion along the white
matter tracts into the hemisphere contralateral to the
tumour site. [18F]PBR06 showed uptake beyond the region
identified with MRI T2-weighted images and highlighted
the infiltrative growth in the contralateral hemisphere. This
result suggests that TSPO PET imaging could potentially
serve as a non-invasive tool to evaluate the disease extent.
Similar to our previous study [22], [18F]PBR06 imaging
reflected TSPO expression in neoplastic cells rather than
GAMs.
In vitro models
The TSPO has been widely studied in glioma cell lines, but
it is still unclear whether this molecule has causative or
contributory role in tumorigenesis or whether up-regulation
represents an epiphenomenon accompanying cancer [23].
Providing a detailed summary of preclinical research is
beyond the scope of this review; we will therefore discuss
studies that may contribute to a more accurate interpreta-
tion of molecular imaging results.
The work by Bode and colleagues [23] can be relevant
to PET imaging, as it suggests that the down-regulation of
TSPO correlates with an aggressive phenotype. The
authors exploited the human glioma cell line U118MG to
look at the effects of TSPO knockdown and exposure to
increasing doses of PK11195 on tumourigenesis. Tspo gene
silencing resulted in a reduction in adhesion molecules,
increased migration in the Boyden chamber, bigger lesions
with ragged margin when implanted in chorioallantoid
membrane, reduced cell death, increased proliferation,
decreased contact inhibition and increased angiogenesis.
Implants of TSPO-negative U118MG cells in xenografts
were much larger than controls. Bode and colleagues’ data
contrasts with the work discussed above [21] and our study
[22] that observed high TSPO level in the infiltrative front
of gliomas. Such discrepancies reiterate the fact that dif-
ferent preclinical models and studies based on clinical
samples can produce inconsistent results.
The residence time, which is defined as the ratio
between injected activity and accumulated ligand in a
target organ, is an important parameter to characterize
radiolabeled ligands and even more so when imaging
ligands that need to be exploited as anti-cancer drugs. PET
imaging studies have examined the residence time of TSPO
tracers in the brain of healthy adults and children [24] and
subjects with neuroinflammation [25], but little is known of
the effect of long-term stable occupancy. To date, only one
preclinical study has addressed this question [26]. Costa
and colleagues used the synthetic compound irDE-MPIGA
that is designed to bind TSPO covalently and permanently
at nanomolar doses, alongside the reversible TSPO ligand
PIGA to investigate the effects of stable and transient
residence time in the human glioma cell line U87MG cells.
A nanomolar dose of irDE-MPIGA induced the early
phases of apoptosis, but 24 h treatment caused only a 40 %
abolition of the [3H]PK11195 binding and RT-PCR anal-
ysis showed that TSPO mRNA levels increased indicating
restoration of TSPO synthesis. These results suggest that
direct pharmacological targeting of TSPO may not be
effective in gliomas.
Although unrelated to CNS tumours, two studies have
provided valuable data to TSPO imaging in neuro-oncology.
The experiments byKlubo-Gwiezdzinska and colleagues [27]
in thyroid carcinoma cell lines knocked down for TSPO
showed sixfold increase of TSPO transcript following expo-
sure to valproic acid. Induction of TSPO by valproic acid was
also associated with increased sensitivity to oxidative stress
after challenge with H2O2. In this model, proliferation, cell
viability andmigrationwere not different between TSPO-rich
and TSPO-deficient cells and were unaffected by silencing of
the TSPO gene. By exploiting the dataset available in Geo
Profiles (http://www.ncbi.nlm.nih.gov/geoprofiles), the
authors observed a reduction in TSPO expression in aggres-
sive and recurrent tumours. The data presented in this study
can be relevant to patientswithCNS tumours.Evidence-based
guidelines suggest that levetiracetam is the best first-line agent
for treatment of seizures in patients with low-grade glioma,
but approximately one-third of such patients have refractory
epilepsy requiring other agents including valproic acid [28].
Similar to Bode et al. [23], the evidence of a positive corre-
lation between low TSPO and aggressive behaviour suggests
that increased binding of TSPO ligands to tumour tissue is not
always a prognostic indicator of poor outcome as previously
widely believed.
Little is known about the regulation of TSPO synthesis.
Gene amplification does not appear to be sufficient to
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explain the increased TSPO in cancer cells. Batarseh and
colleagues [29] published the first in-depth description of
the human TSPO gene promoter and its transcriptional
regulation. With the breast cancer cell lines MCF-7 and
MDA-MB-231 performing as models of high and low
TSPO gene promoter methylation, they demonstrated that
promoter silencing was not the only epigenetic mechanism
regulating the expression and that the transcription factors
Sp1, Sp3 and Sp4 also contribute to the overall levels of
expression. The authors also proposed that multiple
potential transcription factor binding sites are represented
in the TSPO gene promoter, leading to the suggestion of a
different regulation of this gene in different cell types and
tissues. The histone deacetylase inhibitor TSA induced
TSPO promoter activity and reduced the methylation sig-
nature, suggesting that epigenetic modification of chro-
matin and DNA can contribute to the regulation of
promoter activity. An effort should be made to clarify
epigenetic regulation of TSPO gene in CNS tumour entities
before embarking on TSPO imaging studies.
TSPO and brain metastases
Brain metastases are the most common intracranial neo-
plasms. Their prevalence outnumbers primary CNS
tumours by around ten times and represents a leading cause
of death in cancer patients [30, 31]. The incidence of brain
metastases has been increasing steadily over the last decade
as a result of more effective treatments for primary cancer,
thereby increasing the duration of patient survival. All
types of cancer can potentially metastasize to the CNS,
with lung, breast and renal carcinomas and melanomas
representing more than 90 % of deposits [30]. Despite the
extensive screening of TSPO in cancer types outside the
CNS [32] and the association of high TSPO with disease
progression and diminished survival [33], TSPO in brain
metastases from solid cancer is still unexplored territory.
The only brain metastasis model has recently been
published by O’Brien and colleagues [34]. The mouse
mammary carcinoma 4T1 known to express negligible
TSPO was injected into the brain or heart of the animals to
explore the early changes occurring in astrocytes and
microglia. To do so, they used 123I-DPA713 SPECT
imaging, immunohistochemistry and ex vivo autoradiog-
raphy. Following both intracerebral and intracardiac
injection, the authors observed an association between
metastases and reactive astrocytosis in the surrounding
tissue that persisted across the 28-day time course. Astro-
cytosis positively correlated with the volume of the deposit
in intracerebral implants with a constant ratio between
tumour cells and reactive astrocytes described. In contrast,
the ratio of reactive astrocytosis and tumour area increased
significantly following intracardiac injection, which results
in haematogenous spread. Both models showed microglial
activation at the sites of the deposit. Astrocytes and
microglia expressed TSPO, but the degree of expression
varied between the different types of implants. The con-
clusion that microglial and astrocytic TSPO represent a
surrogate marker of metastatic deposit when neoplastic
cells are negative or express low TSPO level is relevant to
imaging studies. Interestingly, ex vivo autoradiography
123I-DPA713 highlighted glial activation in the intracardiac
model, but in vivo SPECT failed to demonstrate individual
metastases. The reason for such a discrepancy is unclear.
The heterogeneity of cell types expressing TSPO in
metastatic deposits was also proved by Zheng and col-
leagues [35] after subcutaneous inoculation of the high
TSPO MDA-MB-231 breast cancer line and low TSPO
MCF-7. The tissue was examined autoradiographically
with the TSPO ligand [18F]DPA-714 and by immunohis-
tochemistry. Both neoplastic cells and macrophages con-
tributed to the overall TSPO load. TSPO did not directly
correlate to the tumour growth rate, metastatic potential or
drug responsiveness. Unlike gliomas, the majority of
macrophages associated with metastases were TSPO pos-
itive, but differences existed among the cell types, with one
having the lowest macrophage density and one triggering
the highest macrophage response. Lymphocytes and neu-
trophils were also shown to contribute to TSPO signal.
The TSPO in gliomas: clinical studies
and methodological consideration
The quantification of TSPO in PET imaging studies is
challenging and brain tumours are not an exception. Pre-
clinical models have not been successfully translated into
clinical studies, due to the differences between human and
animal biology and the fact that animal studies are per-
formed in controlled conditions. An overview of methods
for quantification of binding potentials has recently been
provided by Hinz [36].
Quantification of binding potentials generally requires
an ‘‘input function’’, providing an estimate of kinetic tracer
delivery to the tissue. It can be achieved by multiple
arterial blood samples with correction of tracer activity due
to metabolites, but this is not always practically possible.
Alternatively, the time–activity curve (TAC) of an unaf-
fected region or tissue can be used as a reference under the
general assumption that the tissue selected as reference has
very low TSPO expression, while perfusion is similar to
tumour tissue. Another option is the use of pseudo-refer-
ence regions derived from kinetic tracer analysis in brain
tissue, the ‘‘supervised cluster input function’’ [37].
Reference region approaches may have limitations in
patients with CNS tumours. No data are available on the
extent of microglial TSPO density in the tissue distant from
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the tumour epicentre. Patients with intrinsic brain tumours
often suffer from epilepsy, which is known to trigger
widespread microglial activation [38]. Badie and Schartner
[39] documented microglial activation in the tissue distant
from the tumour in their glioma mouse model, indicating
widespread inflammation. They observed that macrophages
were concentrated within the glioma tissue and its
periphery, while microglia were distributed throughout the
CNS including the hemisphere opposite to that of the
implanted tumours. The authors suggested that such a
distinctive distribution could be explained by the differ-
ences in the migratory capacity and possibly the CNS
immune surveillance function of microglia, as compared to
macrophages.
The TSPO is ubiquitously expressed in endothelial and
smooth muscle cells of vessels and such expression might
potentially obscure the signal from neoplastic cells. Bind-
ing to vascular TSPO appears to be particularly relevant for
tracers with very high affinity, such as 11C-PBR28 and
other ‘‘second-generation’’ tracers. It may require the
introduction of a specific irreversible vascular binding
compartment into the kinetic model [40], a problem which
has not been encountered in preclinical studies. Also, there
is no precise information on TSPO in newly formed vessels
in high-grade astrocytomas and oligodendrogliomas and on
whether the altered conformation of normal vessels that are
distorted by tumour growth might affect the modelling. The
polymorphism rs6971 leading to the amino acid substitu-
tion A147T represents an additional problem, as it causes a
variation in the binding affinity of new compounds [41].
Genotyping for this polymorphism in patients with CNS
tumours would therefore be required before enrolment in
TSPO imaging studies. Finally, methodological approaches
and interpretation of results are hampered by the lack of
understanding of TSPO functions and the inconsistency of
results obtained in in vitro and in vivo experiments. To
stress such uncertainty, Selvaraj and Stocco [42] even
questioned the word ‘ligand’ for TSPO studies. They
remind the readers that ‘ligand’ refers to a small molecule
that binds to a target and elicits or modulates a specific
agonist or antagonist response directly associated with the
function of the target molecule. The evidence that
PK11195 can bind the F0F1 ATP synthase [43] within the
hydrophobic chain region of lipid membranes [44] adds
further complexity.
Despite the limitations discussed above, our work [22,
44] proved the suitability of [11C]-(R)-PK11195 in
molecular imaging of low- and high-grade gliomas, and
its potential to identify anaplastic transformation
(Fig. 1). Binding was modelled using the cerebellum as
the reference, providing more robust results in this
patient group than the supervised cluster input function.
Using this approach, negative binding potentials were
recorded in most WHO grade II gliomas, indicating that
TSPO binding in the cerebellum was higher than in
those tumours. We observed only limited impact of the
blood–brain barrier disruption on the profiles of tracer
kinetics and our results indicated that TSPO PET could
be more sensitive than structural imaging in the early
detection of anaplastic transformation. By quantifying
the intensity and surface of TSPO-positive cytoplasm in
the tissue removed at surgery from the same patients
who underwent 11C-(R)-PK11195 PET imaging, we
could correlate tissue expression with imaging data and
determine the threshold below which 11C-(R)-PK11195
uptake does not appear to be detectable at imaging
(Fig. 2a, b). Notably, cells in the infiltrative component
were as positive as cells in the tumour centre (Fig. 2c,
d). We also proved that TSPO is predominantly
expressed in neoplastic cells, with GAMs only partially
contributing to PET signal and, similar to Winkeler et al.
[19], we found no expression in reactive astrocytes
(Fig. 3a, b). Oligodendrogliomas demonstrated higher
11C-(R)PK11195 binding than expected from tissue
analysis. Their vascular density is evident in rCBV maps
and the tortuosity of vessels [45] may account for such
discrepancy (Fig. 3c, d). In addition, the higher micro-
glial TSPO and perhaps a varying affinity across oligo-
dendrogliomas may contribute to the distinct kinetic.
Three other PK11195 PET studies have been conducted
in a small number of glioma patients. Juncket al. [8] per-
formed the first [11C]-PK11195 PET study in human
astrocytomas. They showed increased uptake in the late
images in eight out of ten patients and suggested that such
accumulation of [11C]-PK11195 represented saturable
high-affinity binding to TSPO. However, they did not
investigate the cellular sources of the binding, nor did they
observe any correlations between tumour grade and tumour
radioactivity or in the ratio of tumour over normal grey or
white matter. The low specific radioactivity of [11C]-
PK11195 in some cases and the use of racemic tracer might
have led to underestimation of the binding. Subsequently,
Pappata et al. [46] demonstrated in a patient with GBM that
[11C]-PK11195 binding was twofold higher in the tumour
than in the normal grey matter and that 30 % of binding in
the tumour could be displaced by a large excess of unla-
belled ligands. Their finding confirmed that [11C]-PK11195
retention in the tumour was in part due to specific binding.
Again, the cellular source of the binding was not men-
tioned. Later on, in a PET investigation of two patients
with anaplastic astrocytoma, Takaya et al. [47] pointed out
that [11C]-R-PK11195 binding was markedly lower in the
tumours than in the contralateral grey matter. Tissue
examination revealed that GAMs failed to express TSPO,
although both tumours contained a substantial number of
microglia.
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TSPO and SPECT
The availability of radiolabelled TSPO ligands for SPECT
could potentially allow the clinical application on a larger
scale because of its relatively low cost [48]. Ro5-4864 was
radiolabelled with iodine-125 to yield a SPECT tracer [49].
Subsequently, a 123I-labelled analogue of PK11195 dis-
played selective binding to the TSPO in human GBM cells
[50]. A [123I]-iodo-PK11195 is currently used in human
SPECT as it has sufficient specific activity for quantitative
studies [51]. Feng et al. [52] scanned four patients with
GBM and six patients with stroke, aiming to streamline the
best 123I-CLINDE quantification approaches for clinical
studies. They reported a 1.8- to 3.4-fold higher distribution
volume of the tracer in the GBMs compared with that in the
cerebellum, and no significant changes in 123I-CLINDE
binding parameters in areas of gadolinium leak. They
concluded that 123I-CLINDE binding was not importantly
affected by BBB disruption, and 123I-CLINDE SPECT
could be used for quantitative assessment of TSPO
expression in vivo.
The SPECT study by Jensen and colleagues [53] is of
interest. They addressed the clinical application of TSPO
imaging in GBM patients by comparing the second-gen-
eration tracer 123I-CLINDE with 18F-FET PET and con-
trast-enhanced structural MRI. The authors studied three
patients with advanced GBM previously genotyped for the
rs6971 polymorphism. None of the subjects received anti-
angiogenesis drugs for 6 weeks before the scans or had any
radio-chemotherapy between scans. They observed limited
volumes of interest (VOI) overlap, indicating that imaging
of 18F-FET and TSPO binding reflects different aspects of
Fig. 1 a Co-registered and fused post-contrast T1-weighted MRI
(greyscale) and parametric BPND images (spectrum colour scale) of
representative cases of LGA, LGO and HGG; note that BPND is low in
LGA, whilst high BPND foci are found in LGO and high BPND areas
in GBM. b Co-registered post-contrast T1-weighted MRI and
parametric BPND images in HGGs showing little or no contrast
enhancement, and high [11C]-(R)-PK11195 binding within the
tumours. The colour bars denote BPND values; the white arrows
indicate tumour location. LGA low-grade astrocytoma, LGO low-
grade oligodendroglioma, AA anaplastic astrocytoma, AO anaplastic
oligodendroglioma, GBM glioblastoma, HGG high-grade glioma
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the tumour. In addition, 18F-FET uptake was shown to be
not entirely specific to glioma cells, although it should not
bind to GAMs. In this respect, the authors suggested that
the TSPO-negative/18F-FET–positive areas represent
reactive astrocytosis. 18F-FET VOIs gave a better overlap
with contrast-enhanced VOIs than 123ICLINDE VOIs and
the signal of 123I-CLINDE was not increased in the areas of
contrast enhancement where the BBB was disrupted.
Finally, the VOIs of increased 123I-CLINDE at baseline
appeared to be a good predictor of tumour progression,
suggesting a potential for TSPO imaging to provide clini-
cally relevant information regarding areas of proliferation.
What have we learnt from pathology?
The extent and distribution of TSPO in the tissue of human
gliomas has been evaluated in a few studies.
It is now 20 years since Miettinen et al. [54] first doc-
umented an association between TSPO level and WHO
grade in a series of 86 surgically removed adult supraten-
torial astrocytomas. Tumours were classified and graded
according to the 1993 edition of the WHO Blue Book; on
WHO grade II and III may not therefore be directly com-
parable with more recent studies. The authors showed that
transcript and protein are undetectable in the normal brain
and found negligible expression in pilocytic astrocytomas.
With the caveat of classification, grade II and III tumours
showed moderate expression without significant difference
between the two grades and with some cases being nega-
tive. Expression in GBM was the highest and uniform in all
but 5 of the 37 cases examined. Similar to our recent study,
Miettinen et al. proved that TSPO increased irrespective of
cell density and found that increased protein levels
depended on increase in gene expression. Vlodawsky et al.
Fig. 2 Analysis of the tissue from the surgery of patients who had
[11C]-(R)-PK11195 demonstrates high TSPO expression in high-
grade astrocytomas; the images document a case of anaplastic
astrocytoma, WHO grade III (a haematoxylin-eosin; 910) and the
extent of TSPO expression in neoplastic cells (b TSPO
immunoperoxidase; 920); TSPO expression is much lower in low-
grade astrocytoma (WHO grade II) (c haematoxylin–eosin; 910), but
retained in the infiltrative component (d TSPO immunoperoxidase;
920)
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[55] found similar levels and distribution of expression in
their series of 130 astrocytomas classified according to the
1999 edition of the WHO classification. There was no
detectable expression in the normal control brains or in the
normal brain tissue that was present in surgical samples.
Pilocytic astrocytomas were virtually negative. Interest-
ingly, none of these studies mentioned endothelial TSPO or
its expression in microglia and macrophages. An interest-
ing discovery of endogenous TSPO ligand diazepam-
binding inhibitor in the same cells expressing TSPO sug-
gests an autocrine loop [54].
Both studies documented a statistically significant
association between TSPO levels and cell proliferation
determined with MIB-1, leading to the suggestion that
TSPO activity is somehow related to the latter. However,
the effect of tumour grade was not considered in the
analysis. Vlodawsky and colleagues also found a linear
correlation between TSPO expression and number of cells
in apoptosis with an increase of both in the cells lining
necrotic areas. Though interesting, this observation did not
consider the presence of macrophages at the edge of the
necrotic tissue; which can be TSPO positive and present to
scavenge apoptotic cells [56]. In addition, the macrophages
themselves can undergo apoptosis as shown in
atherosclerotic plaques [57].
Both studies observed a positive and significant associ-
ation between TSPO expression, WHO-designated tumour
grade and survival. To understand if the association
between TSPO expression and patient survival simply
reflected the association with WHO grade, Mittienen et al.
[54] looked separately at the WHO grade II astrocytomas
group and confirmed that lesions with higher TSPO had a
Fig. 3 The double immunofluorescence staining for TSPO and the
microglial/macrophage marker Iba1 showed that only some micro-
glial cells were TSPO positive (a anaplastic astrocytoma; TSPO green
Alexa Fluor 546 and Iba1 red Alexa Fluor 488; 910); there was no
colocalization of TSPO green Alexa Fluor 546 and GFAP-positive
reactive astrocytes (b anaplastic astrocytoma; TSPO green Alexa
Fluor 546 and Iba1 red Alexa Fluor 488; 920); endothelial cells
express TSPO in a leptomeningeal artery (c low-grade astrocytoma;
TSPO green Alexa Fluor 546 and CD31 red Alexa Fluor 488; 920)
and in a capillary (d, low-grade oligodendroglioma; TSPO green
Alexa Fluor 546 and Iba1 red Alexa Fluor 488; 940)
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tendency for shorter survival time. Analysis of the GBM
group did not reveal any difference. Results on low grades
are interesting, but based on few cases and potentially
flawed by the grading of these lesions based on the 1993
criteria that did not allow reliable distinction between
pilocytic and diffuse astroctyomas.
Buck et al. [21] corroborated their preclinical work with
the evaluation of TSPO in cohort of low- and high-grade
astrocytomas using immunohistochemistry on tissue
microarrays. The extent and distribution of expression were
similar to the previous studies. They found the TSPO
confined to the cytoplasm with only occasional nuclear
expression.
Our recent results [22] are in line with the studies
discussed above. We observed cytoplasmic, granular
immunolabelling for TSPO consistent with mitochondrial
localization. TSPO-positive cells were evenly distributed
throughout the tumour tissue as well as in its peripheral,
infiltrative component as seen by Buck and colleagues in
their preclinical model [21]. The intensity of TSPO
immunolabelling ranged from weak and limited to a
perinuclear cytoplasm in low grades to intense in the
entire cytoplasm anaplastic astrocytomas and GBMs. As
mentioned before, only a proportion of GAMs were
positive and no expression was observed in reactive
astrocytes.
Does TSPO offer advantages over other imaging
modalities?
The question on whether TSPO molecular imaging offers
any advantages over structural, physiological and meta-
bolic imaging, and over other existing molecular imaging
modalities, remains open.
The results from preclinical and clinical studies seem to
suggest an advantage of TSPO PET imaging over structural
and physiological MRI in detecting early transformation
and the infiltrative edge of gliomas. Longitudinal studies
are nevertheless necessary to confirm this suggestion and
investigate the potential of PET in discriminating between
disease progression and radiation necrosis.
TSPO imaging may also offer advantages over
[18F]FDG PET as image interpretation is not affected by
high uptake in the normal brain. Future studies are required
to compare TSPO imaging with amino acid PET. Amino
acid tracers, such as [11C]MET, [18F]FET and [18F]-
FDOPA, depend on an active transport through the
endothelium which is already increased in most low-grade
gliomas in the absence of BBB disruption [58]. Interest-
ingly, FDG and amino acid tracers also demonstrate higher
uptake in oligodendrogliomas than in astrocytomas of the
same grade [59, 60].
The TSPO in the treatment of brain tumours
It is our opinion that molecular imaging can play a role in
developing personalised treatment strategies for patients
with CNS tumours by exploiting the substantially increased
levels of TSPO in high-grade gliomas compared to the
normal brain. However, we agree with Selvaraj and Stocco
[42] that a considerable effort is still necessary to untangle
the functions of TSPO before considering the TSPO as a
primary treatment target.
The use of anticancer drug conjugated to TSPO ligands was
suggested for selective brain delivery, particularly in lesions
where the BBB is preserved [61]. Polyethylene glycol-phos-
phatidyl ethanolamine micelles [62] and dendrimers loaded
with chemotherapeutics and coated with TSPO ligands [63]
were also proposed to enhance the delivery in tumour tissue.
The supposed role of TSPO in maintaining and reestablishing
cell homoeostasis following oxidative stress could also be
exploited in TSPO-positive tumours to increase radio and/or
chemosensitivity to compounds that are routinely used in the
treatment of patients with CNS cancer. However, caution
should be exercised while planning studies that target TSPO,
due to its widespread expression outside the CNS and adrenals,
kidney liver and thyroid, in particular.
The development of nanoparticles and vehicles that
could exploit TSPO to increase the bioavailability and
selective delivery of radiosensitizers into tumour tissue and
enhance the effect of conventional fractionated radiation
seems promising. In fact, selective target of neoplastic cells
with sparing of normal tissue, recognition of intracellular
targets and stability of delivered chemical components
remain one of the most difficult challenges in the clinical
application of radiosensitizers that have not completely
been resolved [64–66].
Conclusion
Research on TSPO in CNS tumours is still at its early
phase. The results obtained in gliomas are promising and
suggest that TSPO imaging can predict anaplastic trans-
formation and progression, allow better delineation of the
infiltrative component and stratification of patients in view
of individualized treatment (see highlights). Research
should address the understanding the functions of TSPO in
human CNS tumours and the evaluation of the extent of
expression in the various entities.
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